Chen, Xuwang published the artcileNovel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors, HPLC of Formula: 56-05-3, the publication is Bioorganic & Medicinal Chemistry Letters (2013), 23(24), 6593-6597, database is CAplus and MEDLINE.
A series of novel piperidinylamino-diarylpyrimidine (pDAPY) derivatives with dual structural conformations was designed through a mol. hybridization strategy and expected to bind into the non-nucleoside inhibitor binding pocket (NNIBP) of HIV-1 RT in a flexible manner. A cell-based antiviral screening assay showed that some compounds were active against both wild-type and drug-resistant mutant virus strains (K103N+Y181C RT) of HIV-1, (4-(2-(4-cyanophenylamino)-6-(1-(pyridin-4-yl-methyl)piperidin-4-yl-amino)pyrimidin-4-yloxy)-3,5-dimethylbenzonitrile with EC50 = 0.047 and 4.6 μM, selectivity index = 2145 and 22, resp.). Mol. simulation studies indicated that 4-(2-(4-cyanophenylamino)-6-(1-(pyridin-4-yl-methyl)piperidin-4-ylamino)pyrimidin-4-yloxy)-3,5-dimethylbenzonitrile could maintain the key hydrophobic interaction and hydrogen bonds with the NNIBP of two RT/ligand complexes. In particular, it could simultaneously occupy the protein/solvent interface and the entrance channel. Exploring these hybrid mols. with dual binding conformations might provide optional chem. scaffolds as novel HIV-1 reverse transcriptase inhibitors (HIV-1 NNRTIs).
Bioorganic & Medicinal Chemistry Letters published new progress about 56-05-3. 56-05-3 belongs to pyrimidines, auxiliary class Pyrimidine,Chloride,Amine,API, name is 2-Amino-4,6-dichloropyrimidine, and the molecular formula is C4H3Cl2N3, HPLC of Formula: 56-05-3.
Referemce:
https://pubchem.ncbi.nlm.nih.gov/compound/Pyrimidine,
Pyrimidine – Wikipedia